RAP - The Next Phase, page-2

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 2 Last

Share
Profile

Follow
Tech goose

2,713 Posts.

506

16/05/16

10:00

Post #: 17774693
Share

Originally posted by Wise_One ↑

Hi All, as a RAPper from the beginning, I thought it would be nice to provide a summary of where we are and what we have to expect over the remainder of Q2 for which we now officially enter the 2nd half of the quarter!

From a news-flow perspective, the next 6 weeks could see the following Anns:
- Partner for US trial (imminent)
- Interim Adult trial results
- Update on WHO partnership (possible)
- MOU with telehealth provider (possible)
- Global Expansion Update (possible - see below for more detail)
- FDA Submission (end of Q2)

I would also like to reinforce some excellent points from the latest investor presentation (3 May - note the relevant page numbers of the slides below) which include:
- Targeting parallel approval in Europe (CE MARK) - page 11
- "Active Partnership Discussions in ALL regions" - page 11
- "Clinical collaborations to be announced shortly" - page 13
- "Potential European, Australian and Asian market entry in parallel to US" - page 16

With all of this taken in to consideration, coupled with the passing of 4-weeks since the CR to allow for staggers to exit, it is no coincidence that we saw a rush of volume / price late last week which IMO will continue and be consistently strong until the end of Q2.

Also note that we are presenting in the "ASX Spotlight Series - Asia" in Singapore (24-May) and Hong Kong (26-May). It has been a nice pattern of late that huge milestones are ticked off prior to a fresh round of investor briefings and again, the timing of these presentations to international investors is no coincidence IMO.

I am expecting one of the above milestones to be announced this week which should see RAP hit all time highs (>32c) and then there will be no stopping the train as the remainder of the Q2 milestones are ticked off.

Longer term, $1-$2 by FDA approval is well & truly in sight which will see RAP become a >$1B Mkt Cap company before the end of the year!

A final little note is that we have been consistently trading above 150m Mkt Cap for a while now which will put us in line for ASX300 admission upon the next index rebalance. This will see mandatory buying from index related funds... adding to the RAP demand!!

Expand

Thanks wise one...happy days ahead

RAP Price at posting: 25.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

NOX

Noxopharm gets HERACLES autoimmune trials started with first human doses

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

MGX

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

WCE

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

IMU

Wednesday's HotCopper trends: Imugene cap-raise, Lumos distribution deal | July 16

There are more pages in this discussion • 2,114 more messages in this thread...

First 2 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

RAP - The Next Phase, page-2

Top Stories

Noxopharm gets HERACLES autoimmune trials started with first human doses

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

'Exceptional start' for West Coast Silver in Elizabeth Hill's maiden drill run

Wednesday's HotCopper trends: Imugene cap-raise, Lumos distribution deal | July 16

Featured News